RxDoctor Payments Data

Rimon Shaker, MD

Cardiovascular Disease · Redlands, CANPI 1598940983

Payments from drug & device makers

$3,034in general payments, 2019–2025

Across 57 payments — averaging $53.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Medtronic$440
  • Medical Device Business Services, Inc.$374
  • Abiomed$238
  • Boston Scientific$212
  • Biosense Webster, Inc.$205
  • plus $219 from 5 others

What the payments were for

  • Travel & lodging$89830%
  • Food & beverage$2,13670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,034 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$93,231
Medicare patients
347
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$179,026
XareltoRivaroxaban50$53,631
Repatha PushtronexEvolocumab18$24,085
EntrestoSacubitril/Valsartan15$21,877
BrilintaTicagrelor17$16,732
Repatha SureclickEvolocumab13$10,206
FarxigaDapagliflozin Propanediol12$9,495
Ranolazine ErRanolazine42$3,187
Metoprolol Succinate109$1,438
ClopidogrelClopidogrel Bisulfate133$1,422
Nitroglycerin37$1,405
Atorvastatin Calcium96$1,097
Potassium Chloride56$1,014
Carvedilol65$977
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$21,87715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →